(Q44430506)

2 December 2017

1 reference

title

Helicobacter pylori eradication. Triple or quadruple therapy?, Long or short treatment? (English)

1 reference

2 December 2017

1 reference

1

1 reference

2 December 2017

2

1 reference

2 December 2017

Gené E

3

1 reference

2 December 2017

publication date

1 May 2003

1 reference

Gastroenterología y Hepatología

2 December 2017

published in

1 reference

2 December 2017

volume

26

1 reference

2 December 2017

issue

5

1 reference

2 December 2017

page(s)

325-329

1 reference

Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la Conferencia Española de Consenso

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Regular review: treatment of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

One-week regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Furazolidone combination therapies for Helicobacter pylori infection in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Rifabutin-based Helicobacter pylori eradication 'rescue therapy'.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

One week eradication regimen for Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Disappearance of gastritis after eradication of Helicobacter pylori. A morphometric study

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Helicobacter pyloriEradication with Doxycycline—Metronidazole—Bismuth Subcitrate Triple Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Factors influencing the eradication of Helicobacter pylori with triple therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Italian omeprazole triple therapy--a 1-week regimen.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Mechanism and clinical significance of metronidazole resistance in Helicobacter pylori.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

[Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care]

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'.

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0210-5705%2803%2970366-5

7 January 2021

10.1016/S0210-5705(03)70366-5

Identifiers

DOI

1 reference

2 December 2017

1 reference